In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
VaxInnate's $30mm Series D supports swine flu vaccine candidate
13 May 2009
Vaccines developer VaxInnate completed a $30mm Series D financing to lead and first-time backer Wellcome Trust, which adds a board member. Returning shareholders CHL Medical Partners, Canaan Partners, HealthCare Ventures, MedImmune Ventures, New Leaf Venture Partners, and Oxford Bioscience Partners also participated. The money will support clinical trials of various infectious disease vaccines, as well as the continued development of a prototype swine flu vaccine, which should enter preclinical studies in about a month. It is possible that at the government's request, VaxInnate could begin manufacturing a swine flu vaccine within weeks of the product's approval to meet the needs of the current global crisis. To date the company has raised about $95mm in venture funding.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?